Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes-Reference-Cited by-同舟云学术

Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes

Published:2018-10-10 Issue:12 Volume:41 Page:e150-e151
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:

Author:

Wright Jordan J.¹,Salem Joe-Elie²³,Johnson Douglas B.⁴,Lebrun-Vignes Bénédicte³,Stamatouli Angeliki⁵,Thomas James W.⁶,Herold Kevan C.⁷,Moslehi Javid²,Powers Alvin C.¹⁸⁹^ORCID

Affiliation:

1. Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

2. Division of Cardiovascular Medicine and Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

3. Department of Pharmacology, Regional Center of Pharmacovigilance, CIC-1421, Pitié-Salpêtrière Hospital, Assistance Publique – Hôpitaux de Paris, Sorbonne Universities, Paris, France

4. Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

5. Section of Endocrinology, Department of Internal Medicine, Yale University, New Haven, CT

6. Division of Rheumatology and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

7. Department of Immunobiology, Yale University, New Haven, CT

8. Department of Molecular Physiology & Biophysics, Vanderbilt University, Nashville, TN

9. Veterans Affairs Tennessee Valley Healthcare System, Nashville, TN

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/care/article-pdf/41/12/e150/527211/dc181465.pdf

Reference5 articles.

1. Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors;Tocut;Autoimmun Rev,2018

2. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors;Stamatouli;Diabetes,2018

3. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis;Barroso-Sousa;JAMA Oncol,2018

4. VigiBase, the WHO global ICSR database system: basic facts;Lindquist;Ther Innov Regul Sci,2008

5. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma;Yamazaki;Cancer Chemother Pharmacol,2015

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune Checkpoint Inhibitors-Associated Diabetes and Ketoacidosis Were Found in FDA Adverse Event Reporting System: A Real-World Evidence Database Study;Endocrine Practice;2024-09

2. Identification of Immune Checkpoint Inhibitor–Induced Diabetes;JAMA Oncology;2024-08-29

3. Toxicity profile of camrelizumab-based immunotherapy in older adults with advanced cancer;Scientific Reports;2024-08-16

4. Immune checkpoint inhibitor‐induced diabetes: Twists and turns of diabetology;Diabetes, Obesity and Metabolism;2024-08-02

5. Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update;Journal for ImmunoTherapy of Cancer;2024-07